The clearest answer to "is more better?" comes from a study that simply tried five doses and measured the results. Sixty-one healthy young men had their own testosterone production suppressed, then received weekly injections of 25, 50, 125, 300 or 600 mg for 20 weeks. Muscle and hemoglobin rose with dose. HDL cholesterol fell with dose. And sexual function, mood and visual-spatial cognition did not change significantly at any dose — including the highest.[1]
That last finding is the one worth sitting with, because the things men most often chase higher numbers for are the things that did not move.
What the five doses produced
The regimen produced mean nadir testosterone concentrations of 253, 306, 542, 1,345 and 2,370 ng/dL across the five groups.[1] The top two are well above the physiological range.
| Measure | Direction with dose |
|---|---|
| Fat-free mass | ↑ dose-dependently — +3.4, +5.2, +7.9 kg at 125, 300, 600 mg[1] |
| Leg press strength, leg power, thigh and quadriceps volume | ↑ positively correlated with concentration[1] |
| Hemoglobin | ↑ positively correlated[1] |
| IGF-I | ↑ positively correlated[1] |
| Fat mass | ↓ negatively correlated[1] |
| HDL cholesterol | ↓ negatively correlated[1] |
| Sexual function | no significant change at any dose[1] |
| Visual-spatial cognition and mood | no significant change at any dose[1] |
| PSA | no significant change at any dose[1] |
The authors' conclusion is that these changes conform to a single linear dose-response relationship — but that different androgen-dependent processes have different dose-response relationships.[1] Which is the precise, unglamorous version of "more is not uniformly better."
Why two of those rows are the safety story
Hemoglobin rising with dose. Erythrocytosis is already the most common side effect of testosterone therapy, with published guidance to reduce or discontinue above a hematocrit of 54%.[2] A dose-dependent rise in hemoglobin means the risk that already needs monitoring scales with the number you are chasing. See erythrocytosis and hematocrit.
HDL cholesterol falling with dose. A negative correlation with testosterone concentration.[1] HDL is not a number most men on treatment are watching, and it moves the wrong way as dose climbs.
Neither is dramatic at replacement doses. Both are reasons the target is what it is.
What the guideline targets, and why that is not timidity
The Endocrine Society suggests aiming at testosterone concentrations in the mid-normal range during treatment.[3] Read against the dose-response data, that is not a cautious compromise — it is where the measured trade-off is best. The benefits men actually report wanting (mood, sexual function, energy) showed no dose-dependence at all in this study, while two risk markers did.
The other trials point the same way. TRAVERSE's sexual function study found testosterone improved sexual activity and desire but not erectile function.[4] Its depression analysis found mood improvements that were real and explicitly small.[5] None of that argues for pushing higher.
The honest limits of this evidence
It was 20 weeks. Long-term consequences of supraphysiological concentrations are not what this study measured.
It was healthy young men, not hypogonadal patients. The dose-response shape is informative; the population is not the one being treated.
"No significant change" is not "impossible." Sexual function was already normal in these men, so there was little room to improve — an important caveat, and a different situation from a man who is genuinely deficient.
What the study does establish firmly is that the muscle response and the risk-marker response both scale with dose, while several of the outcomes people chase do not.
Frequently asked questions
If more testosterone builds more muscle, why not aim high? Because the same dose gradient raised hemoglobin and lowered HDL,[1] and because the guideline's treatment target is mid-normal.[3] Treatment for hypogonadism and maximising a body-composition outcome are different goals with different risk calculus.
My level came back mid-range. Should I ask for more? Mid-normal is the target the guideline sets.[3] Being at it means dose is not the explanation for any remaining symptoms, which redirects the review somewhere more useful.
Does a higher number mean I'll feel better? Not on this evidence. Mood and sexual function showed no significant change across a dose range spanning nadir concentrations from 253 to 2,370 ng/dL.[1]
What about PSA? PSA did not change significantly at any dose in this study.[1] Prostate cancer risk assessment remains part of first-year monitoring regardless.[3]
The practical takeaway
The dose question has been answered experimentally, and the answer is that different things respond differently. Treatment aims at mid-normal because that is where the measured benefit-to-risk trade sits — not because anyone is being conservative for its own sake.
Keen connects you with a licensed clinical team for a telehealth consultation and lab review. If your testosterone is clinically low, treatment is Keen Testosterone Spray Rx — a once-daily topical spray powered by Hypospray® transdermal delivery.
Related reading: erythrocytosis and hematocrit, testosterone and venous clots, and the 3-month panel.
References
5 sources
- Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172–E1181. doi:10.1152/ajpendo.2001.281.6.E1172 · PMID 11701431
- Agrawal P, Singh SM, Kohn T. Management of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide. Eur Urol Focus. 2023;9(1):20–21. doi:10.1016/j.euf.2022.10.008 · PMID 36335038
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
- Pencina KM, Travison TG, Cunningham GR, et al. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. J Clin Endocrinol Metab. 2024;109(2):569–580. doi:10.1210/clinem/dgad484 · PMID 37589949
- Bhasin S, Seidman S, Travison TG, et al. Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy. J Clin Endocrinol Metab. 2024;109(7):1814–1826. doi:10.1210/clinem/dgae026 · PMID 38205962
Practical questions about membership, labs and using the spray are answered in the Learn Hub FAQ.
Hypospray® is a registered trademark. Keen Meds Inc. utilizes the Hypospray® topical transdermal delivery platform under license.